As of Jan 18
| +0.05 / +2.13%|
The 5 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 9.00, with a high estimate of 13.00 and a low estimate of 5.00. The median estimate represents a +275.00% increase from the last price of 2.40.
The current consensus among 7 polled investment analysts is to Buy stock in Regulus Therapeutics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.